Literature DB >> 6619119

A new method for purification of anti-glycosphingolipid antibody. Avian anti-hematoside (NeuGc) antibody.

Y Hirabayashi, T Suzuki, Y Suzuki, T Taki, M Matsumoto, H Higashi, S Kato.   

Abstract

A new method for purification of anti-glycosphingolipid antibodies had been developed. N-Glycolylneuraminyl(alpha 2-3)lactosylceramide [hematoside (NeuGc)] could be hydrophobically bound on octyl-Sepharose 4B in the presence of 0.1 M KCl. The Sepharose gel coated with hematoside (NeuGc) was used as immunoadsorbent for affinity column chromatography to purify avian anti-hematoside (NeuGc) antibody. The procedure is very simple, reproducible and applicable to purification of almost all anti-glycosphingolipid antibodies. The glycosphingolipid used for the affinity chromatography could be recovered without any destruction by successive extraction of the gel with methanol and methanol/chloroform (1:2, v/v).

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6619119     DOI： 10.1093/oxfordjournals.jbchem.a134350

Source DB:  PubMed          Journal:  J Biochem        ISSN： 0021-924X            Impact factor:   3.387


  17 in total

1.  Sialic acid species as a determinant of the host range of influenza A viruses.

Authors:  Y Suzuki; T Ito; T Suzuki; R E Holland; T M Chambers; M Kiso; H Ishida; Y Kawaoka
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Recognition of N-glycolylneuraminic acid linked to galactose by the alpha2,3 linkage is associated with intestinal replication of influenza A virus in ducks.

Authors:  T Ito; Y Suzuki; T Suzuki; A Takada; T Horimoto; K Wells; H Kida; K Otsuki; M Kiso; H Ishida; Y Kawaoka
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Glycosphingolipids of human urothelial cell lines with different grades of transformation.

Authors:  M Ugorski; P Påhlsson; D Dus; B Nilsson; C Radzikowski
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

4.  Human monoclonal IgM with autoantibody activity against two gangliosides (GM1 and GD1b) in a patient with motor neuron syndrome.

Authors:  M O Jauberteau; N Gualde; J L Preud'Homme; M Rigaud; R Gil; J M Vallat; N Baumann
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

5.  Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides.

Authors:  J C Garcia-Monco; R J Seidman; J L Benach
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

6.  Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome.

Authors:  Nobuhiro Yuki; Keiichiro Susuki; Michiaki Koga; Yukihiro Nishimoto; Masaaki Odaka; Koichi Hirata; Kyoji Taguchi; Tadashi Miyatake; Koichi Furukawa; Tetsuji Kobata; Mitsunori Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

7.  Anti-sulphatide antibodies in peripheral neuropathy.

Authors:  L H van den Berg; C L Lankamp; A E de Jager; N C Notermans; P Sodaar; J Marrink; H J de Jong; P R Bär; J H Wokke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

8.  The cell envelope structure of the lipopolysaccharide-lacking gram-negative bacterium Sphingomonas paucimobilis.

Authors:  S Kawasaki; R Moriguchi; K Sekiya; T Nakai; E Ono; K Kume; K Kawahara
Journal:  J Bacteriol       Date:  1994-01       Impact factor: 3.490

9.  Immunohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma.

Authors:  T Saida; S Ikegawa; Y Takizawa; S Kawachi
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

10.  N-glycolylneuraminic acid on human epithelial cells prevents entry of influenza A viruses that possess N-glycolylneuraminic acid binding ability.

Authors:  Tadanobu Takahashi; Maiko Takano; Yuuki Kurebayashi; Midori Masuda; Sawako Kawagishi; Masahiro Takaguchi; Takashi Yamanaka; Akira Minami; Tadamune Otsubo; Kiyoshi Ikeda; Takashi Suzuki
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.